The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia

被引：6

作者：

Gonzalez-Lugo, Jesus D. ^{[1
]}

Chakraborty, Samarpana ^{[1
,2
]}

Verma, Amit ^{[1
,2
]}

Shastri, Aditi ^{[1
,2
]}

机构：

[1] Montefiore Med Ctr, Albert Einstein Coll Med, Div Hematol Malignancies, Dept Oncol, Moses Campus,111 East 210th St,Hofheimer 100, Bronx, NY 10467 USA

[2] Albert Einstein Coll Med, Dept Mol & Dev Biol, Bronx, NY 10467 USA

来源：

SEMINARS IN HEMATOLOGY | 2021年 / 58卷 / 01期

关键词：

D O I：

10.1053/j.seminhematol.2020.12.003

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Mutations in the group of epigenetic modifiers are the largest group of mutated genes in Myelodysplastic Syndromes (MDS) and are very frequently found in Acute Myeloid Leukemia (AML). Our advancements in the understanding of epigenetics in these diseases have helped develop groundbreaking therapeutics that have changed the treatment landscape of MDS and AML, significantly improving outcomes. In this review we describe the most common epigenetic aberrations in MDS and AML, and current treatments that target mutations in epigenetic modifiers, as well as novel treatment combinations, from standard therapies to investigational treatments. (C) 2021 Elsevier Inc. All rights reserved.

引用

页码：56 / 65

页数：10

共 125 条

[1] The molecular hallmarks of epigenetic control [J].

Allis, C. David ;

Jenuwein, Thomas .

NATURE REVIEWS GENETICS, 2016, 17 (08) :487-500

[2] TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients [J].

Bejar, Rafael ;

Lord, Allegra ;

Stevenson, Kristen ;

Bar-Natan, Michal ;

Perez-Ladaga, Albert ;

Zaneveld, Jacques ;

Wang, Hui ;

Caughey, Bennett ;

Stojanov, Petar ;

Getz, Gad ;

Garcia-Manero, Guillermo ;

Kantarjian, Hagop ;

Chen, Rui ;

Stone, Richard M. ;

Neuberg, Donna ;

Steensma, David P. ;

Ebert, Benjamin L. .

BLOOD, 2014, 124 (17) :2705-2712

[3] Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine [J].

Blum, William ;

Garzon, Ramiro ;

Klisovic, Rebecca B. ;

Schwind, Sebastian ;

Walker, Alison ;

Geyer, Susan ;

Liu, Shujun ;

Havelange, Violaine ;

Becker, Heiko ;

Schaaf, Larry ;

Mickle, Jon ;

Devine, Hollie ;

Kefauver, Cheryl ;

Devine, Steven M. ;

Chan, Kenneth K. ;

Heerema, Nyla A. ;

Bloomfield, Clara D. ;

Grever, Michael R. ;

Byrd, John C. ;

Villalona-Calero, Miguel ;

Croce, Carlo M. ;

Marcucci, Guido .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (16) :7473-7478

[4] Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound [J].

Bykov, VJN ;

Issaeva, N ;

Shilov, A ;

Hultcrantz, M ;

Pugacheva, E ;

Chumakov, P ;

Bergman, J ;

Wiman, KG ;

Selivanova, G .

NATURE MEDICINE, 2002, 8 (03) :282-288

[5] The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications [J].

Chao, Mark P. ;

Weissman, Irving L. ;

Majeti, Ravindra .

CURRENT OPINION IN IMMUNOLOGY, 2012, 24 (02) :225-232

[6] Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47 [J].

Chao, Mark P. ;

Jaiswal, Siddhartha ;

Weissman-Tsukamoto, Rachel ;

Alizadeh, Ash A. ;

Gentles, Andrew J. ;

Volkmer, Jens ;

Weiskopf, Kipp ;

Willingham, Stephen B. ;

Raveh, Tal ;

Park, Christopher Y. ;

Majeti, Ravindra ;

Weissman, Irving L. .

SCIENCE TRANSLATIONAL MEDICINE, 2010, 2 (63)

[7] Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment [J].

Chen, Xufeng ;

Glytsou, Christina ;

Zhou, Hua ;

Narang, Sonali ;

Reyna, Denis E. ;

Lopez, Andrea ;

Sakellaropoulos, Theodore ;

Gong, Yixiao ;

Kloetgen, Andreas ;

Yap, Yoon Sing ;

Wang, Eric ;

Gavathiotis, Evripidis ;

Tsirigos, Aristotelis ;

Tibes, Raoul ;

Aifantis, Iannis .

CANCER DISCOVERY, 2019, 9 (07) :890-909

[8] TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics [J].

Chou, Wen-Chien ;

Chou, Sheng-Chieh ;

Liu, Chieh-Yu ;

Chen, Chien-Yuan ;

Hou, Hsin-An ;

Kuo, Yuan-Yeh ;

Lee, Ming-Cheng ;

Ko, Bor-Sheng ;

Tang, Jih-Luh ;

Yao, Ming ;

Tsay, Woei ;

Wu, Shang-Ju ;

Huang, Shang-Yi ;

Hsu, Szu-Chun ;

Chen, Yao-Chang ;

Chang, Yi-Chang ;

Kuo, Yi-Yi ;

Kuo, Kuan-Ting ;

Lee, Fen-Yu ;

Liu, Ming-Chi ;

Liu, Chia-Wen ;

Tseng, Mei-Hsuan ;

Huang, Chi-Fei ;

Tien, Hwei-Fang .

BLOOD, 2011, 118 (14) :3803-3810

[9] 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation:: mechanistic studies and their implications for cancer therapy [J].

Christman, JK .

ONCOGENE, 2002, 21 (35) :5483-5495

[10] APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myelodysplasies (GFM) [J].

Cluzeau, Thomas ;

Sebert, Marie ;

Rahme, Ramy ;

Cuzzubbo, Stefania ;

Walter-petrich, Anouk ;

Che, Jacqueline Lehmann ;

Peterlin, Pierre ;

Beve, Blandine ;

Attalah, Habiba ;

Chermat, Fatiha ;

Miekoutima, Elsa ;

Beyne-Rauzy, Odile ;

Recher, Christian ;

Stamatoullas, Aspasia ;

Willems, Lise ;

Raffoux, Emmanuel ;

Berthon, Celine ;

Quesnel, Bruno ;

Carpentier, Antoine ;

Sallman, David A. ;

Chevret, Sylvie ;

Ades, Lionel ;

Fenaux, Pierre .

BLOOD, 2019, 134

← 1 2 3 4 5 6 7 8 9 10 →